Patents by Inventor Joost Neijssen

Joost Neijssen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
    Patent number: 11932693
    Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
    Type: Grant
    Filed: May 11, 2023
    Date of Patent: March 19, 2024
    Assignees: BioNTech SE, Genmab A/S
    Inventors: Ugur Sahin, Sina Fellermeier-Kopf, Friederike Gieseke, Karsten Beckmann, Claudia Paulmann, Alexander Muik, Ivan Kuzmanov, Esther Cornelia Wilhelmina Breij, Patricia Garrido Castro, Jordan Blum, Lars Guelen, Joost Neijssen, Bart-Jan De Kreuk, Richard Hibbert, Janine Schuurman, Aran Frank Labrijn
  • MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE
    Publication number: 20230365693
    Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 16, 2023
    Inventors: Ugur SAHIN, Sina FELLERMEIER-KOPF, Friederike GIESEKE, Karsten BECKMANN, Claudia PAULMANN, Alexander MUIK, Ivan KUZMANOV, Esther Cornelia Wilhelmina BREIJ, Patricia GARRIDO CASTRO, Jordan BLUM, Lars GUELEN, Joost NEIJSSEN, Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran Frank LABRIJN
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20210395373
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 23, 2021
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20200087407
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20180258173
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 13, 2018
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20170275367
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 28, 2017
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/c-Met antibodies
    Patent number: 9695242
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 4, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20170101475
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/c-Met antibodies
    Patent number: 9593164
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 14, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/c-Met antibodies
    Patent number: 9580508
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: February 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20140255408
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20140141000
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: November 21, 2013
    Publication date: May 22, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman